Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 8/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | KIF5B | P33176 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16783662 | 0.94 | PIK3CD (0.35) | PIK3CDEGFRJAK2JAK3PIK3CG | |
| SCHEMBL21337803 | 0.92 | PIK3CD (0.38) | PIK3CDSOS1PIK3CG | |
| SCHEMBL16806438 | 0.90 | KIT (0.36) | PIK3CDEGFRJAK2JAK3PIK3CG | |
| SCHEMBL16783524 | 0.90 | PDK4 (0.41) | PIK3CDEGFRPIK3CG | |
| SCHEMBL16783545 | 0.89 | LNPEP (0.39) | PIK3CDPIK3CGPIK3R1CSNK1ERET | |
| SCHEMBL16806425 | 0.89 | PIK3CD (0.37) | PIK3CDPIK3CGPIK3R1CSNK1ERET | |
| SCHEMBL16806439 | 0.89 | ATR (0.39) | PIK3CDEGFRJAK2JAK3 | |
| Hydrochloric Acid SCHEMBL16783635 | 0.88 | PIK3CD (0.36) | PIK3CDSOS1PIK3CGPIK3R1CSNK1E | |
| SCHEMBL16806437 | 0.88 | PIK3CD (0.32) | PIK3CDEGFRJAK2JAK3PIK3CG | |
| Formic Acid SCHEMBL16783606 | 0.88 | KIT (0.35) | PIK3CDEGFRJAK2JAK3PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083617-B1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-09-11 | — | — | EP | disclosed |
| EP-3083617-B1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-09-11 | — | — | EP | disclosed |
| EP-3083617-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2016-10-26 | — | — | EP | disclosed |
| US-9321776-B2 | Isochromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-26 | — | — | US | disclosed |
| US-9321776-B2 | Isochromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-26 | — | — | US | disclosed |
| US-9321776-B2 | Isochromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-26 | — | — | US | disclosed |
| WO-2015091685-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091685-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-25 | — | — | WO | disclosed |
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-18 | — | — | US | disclosed |
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-18 | — | — | US | disclosed |
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | PIKFYVE, IP6K2, IP6K3 | PIK3CD 15/4885SOS1 1128/4885EGFR 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.